Relay Therapeutics Names Jami Rubin to Its Board of Directors

CAMBRIDGE, Mass.–(BUSINESS WIRE)–#oncology—Relay Therapeutics, a new breed of company at the intersection of computation and biotechnology, today announced the appointment of Jami Rubin to its board of directors.

Relay Therapeutics is focused on delivering therapies to patients against validated but previously intractable targets. It has made significant advances in integrating unprecedented computational power with leading-edge experimental approaches to overcome challenges in drug discovery. This approach has been validated with multiple programs poised to enter the clinic over the coming years. “At this critical point in our trajectory, we are pleased to welcome Jami to our board of directors. Her deep understanding of healthcare, capital markets and strategy will help us navigate the pathway towards getting multiple new therapies to patients. She will be an exceptional partner and advisor as we enter our next phase of growth,” said Sanjiv Patel, M.D., president and chief executive officer of Relay Therapeutics.

“I’m thrilled to be joining the board of Relay Therapeutics. Relay’s drug discovery platform is unique in the biotech industry and has potential to achieve breakthrough treatments for intractable diseases. I couldn’t be more excited to be part of this outstanding team to help shape this groundbreaking company,” said Ms. Rubin.

Ms. Rubin is a partner at PJT Partners, a global advisory-focused investment bank where she advises biotech and pharmaceutical companies on a range of strategic matters. Prior to joining PJT Partners, she spent more than 25 years as an equity analyst following the pharmaceutical industry. Most recently, Ms. Rubin was a partner at Goldman Sachs, where she was a top ranked analyst and responsible for managing the global healthcare research team. Ms. Rubin received her B.A. in history from Vassar College. She serves on the board of Gilda’s Club NYC.

About Relay Therapeutics

Relay Therapeutics is committed to creating medicines that will have a transformative impact on patients by building a unique discovery platform centered on understanding how the conformation of proteins relate to function. Whereas prior approaches to imaging proteins have been limited to static pictures, Relay Therapeutics’ approach overcomes this challenge by combining unprecedented computational power with leading edge experimental techniques in structural biology, biophysics, chemistry and biology. This integration illuminates – for the first time – the full mobility of a protein and provides key insights into how the dynamic nature of a protein’s conformation regulates function. By applying these insights, Relay Therapeutics aims to modulate protein conformation to develop novel therapies for patients. The company’s initial programs are focused on developing therapeutics in oncology. Headquartered in Cambridge, Massachusetts, Relay Therapeutics is a private company launched in 2016. To date the company has raised $520M from investors including SoftBank Vision Fund, Third Rock Ventures, Casdin Capital, GV, BVF Partners, EcoR1 Capital, Foresite Capital, Perceptive Advisors, Tavistock Group and an affiliate of D.E. Shaw Research.

Contacts

Katie Engleman

1AB

[email protected]